Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep:142:109815.
doi: 10.1016/j.mehy.2020.109815. Epub 2020 May 6.

Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?

R Derwand  1 , M Scholz  2
Affiliations

Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?

R Derwand et al. Med Hypotheses. 2020 Sep.

Abstract

Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.

Keywords: COVID-19; Chloroquine; Hydroxychloroquine; SARS-CoV-2; Therapy; Zinc.

PubMed Disclaimer

References

    1. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594... [consulted on 2020-04-22].
    1. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. - PMC - PubMed
    1. Cui-Cui L., Xiao-Jia W., Hwa-Chain R.W. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today. 2019;24(3):726–736. - PMC - PubMed
    1. Smith T, Bushek J, Prosser, T. COVID-19 drug therapy potential options. Clinical drug information, clinical solutions. https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Dru... [consulted on 2020-03-28].
    1. Colson P., Rolain J.M., Lagier J.C., Brouqui P., Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105932. published online Mar 4. - DOI - PMC - PubMed

MeSH terms